Business Context and Reporting Period
Daré Bioscience, Inc. (Nasdaq: DARE) filed a Current Report on Form 8-K dated August 14, 2026. The filing announces the entry into a material definitive agreement for a private placement of equity securities with certain institutional investors. The company is a Delaware corporation focused on 503B compounding and consumer health strategies.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Aggregate Gross Proceeds: Approximately $6.0 million (before offering expenses and excluding warrant exercises).
- Offering Price: $1.37 per share of common stock and $1.3699 per pre-funded warrant.
- Securities Issued:
- 4,085,687 shares of common stock.
- 293,894 pre-funded warrants (exercise price $0.0001).
- 4,379,581 Series A Warrants (exercise price $1.37, 5-year term).
- 4,379,581 Series B Warrants (exercise price $1.37, 2-year term).
- Placement Agent Fees: 7.0% of gross proceeds plus reimbursement of expenses up to $105,000, plus 4.0% of shares/pre-funded warrants issued as warrants to the agent.
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity and warrants. The transaction is expected to close on or about August 17, 2026, subject to customary conditions. There is no prior comparable period data provided in this specific filing to assess operational changes.
Guidance, Outlook, and Risks
Use of Proceeds: The company intends to use the net proceeds for working capital and general corporate purposes, specifically to support its 503B compounding and consumer health business strategies, research and development, and general administrative costs.
Warrant Terms and Risks:
- Exercise Restrictions: Holders cannot exercise warrants if it would result in ownership exceeding 4.99% (or 9.99% at election) of outstanding common stock.
- Stockholder Approval: Exercise of Common Warrants is subject to Nasdaq rules requiring stockholder approval; they become exercisable only after such approval is obtained.
- Fundamental Transactions: Warrants include cash redemption rights based on Black-Scholes Value in the event of a fundamental transaction.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received, as the filing states the closing is "expected" on August 17, 2026.
- Confirm the status of stockholder approval required for the exercise of Series A and Series B Warrants.
- Review the company's most recent 10-Q or 10-K to assess current cash runway and liquidity needs, as this 8-K does not contain balance sheet data.
- Monitor the dilution impact of the 4,379,581 Series A and Series B Warrants upon potential exercise.